SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Kocher MS, Kasser JR 2003 Osteopetrosis. Am J Orthop 32: 222228.
  • 2
    Whyte MP 2003 Genetic, developmental, and dysplastic skeletal disorders. In: FavusMJ (ed.) Primer on Metabolic Bone Diseases and Disorders of Mineral Metabolism. American Society for Bone and Mineral Research, Washington, DC, USA, pp. 449466.
  • 3
    Sobacchi C, Frattini A, Orchard P, Porras O, Tezcan I, Andolina M, Babul-Hirji R, Baric I, Canham N, Chitayat D, Dupuis-Girod S, Ellis S, Etzioni A, Fasth A, Fisher A, Gerritsen G, Gulino V, Horwitz E, Klamroth V, Lanino E, Mirolo M, Musio A, Matthijs G, Nonomaya S, Notarangelo LD, Ochs HD, Superti Furga A, Valiaho J, van Hove JLK, Vihinen M, Vujic D, Vezzoni P, Villa A 2001 The mutational spectrum of human malignant autosomal recessive osteopetrosis. Hum Mol Genet 10: 17671773.
  • 4
    Boyce BF 2003 Bad bones, grey hair, one mutation. Nat Med 9: 395396.
  • 5
    Boyle WJ, Simonet WS, Lacey DL 2003 Osteoclast differentiation and activation. Nature 423: 337342.
  • 6
    Teitelbaum SL, Ross FP 2003 Genetic regulation of osteoclast development and function. Nat Rev Genet 4: 638649.
  • 7
    Theill LE, Boyle WJ, Penninger JM 2002 RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 20: 795823.
  • 8
    Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, Daro E, Smith J, Tometsko ME, Maliszewski CR, Armstrong A, Shen V, Bain S, Cosman D, Anderson D, Morrissey PJ, Peschon JJ, Schuh J 1999 RANK is essential for osteoclast and lymph node development. Genes Dev 13: 24122424.
  • 9
    Li J, Sarosi I, Yan X-Q, Morony S, Capparelli C, Tan H-L, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan S-C, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik P, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ 2000 RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 97: 15661571.
  • 10
    Kong Y-Y, Yoshida H, Sarosi I, Tan H-L, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM 1999 OPGL is a key regulator of osteoclastogenesis, lymphocyte development, and lymph-node organogenesis. Nature 397: 315323.
  • 11
    Fata JE, Kong Y-Y, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey DL, Boyle WJ, Khokha R, Penninger JM 2000 The osteoclast differentiation factor osteoprotegrin-ligand is essential for mammary gland development. Cell 103: 4150.
  • 12
    Li P, Schwarz EM, O'Keefe RJ, Ma L, Boyce BF, Xing L 2004 RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNF alpha-mediated inflammatory arthritis. J Bone Miner Res 19: 207213.
  • 13
    Parisi MA, Baldessari AE, Iida MHK, Clarke CM, Doggett B, Shirasawa S, Kapur RP 2003 Genetic background modifies intestinal pseudo-obstruction and the expression of a reporter gene in Hox11L1 -/- mice. Gastroenterology 125: 14281440.
  • 14
    Xing L, Bushnell TP, Carlson L, Tai Z, Tondravi M, Siebenlist U, Young F, Boyce BF 2002 NF-kappaB p50 and p52 expression is not required for RANK-expresing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J Bone Miner Res 17: 12001210.
  • 15
    Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF 1996 Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med 2: 11321136.
  • 16
    Xing L, Carlson L, Story B, Tai Z, Keng P, Siebenlist U, Boyce BF 2003 Expression of either NF-κB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption. J Bone Miner Res 18: 260269.
  • 17
    Armstrong AP, Tometsko ME, Glaccum M, Sutherland CL, Cosman D, Dougall WC 2002 A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem 277: 4434744356.
  • 18
    Soriano P, Montgomery C, Geske R, Bradley A 1991 Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64: 693702.
  • 19
    Johnson RS, Spiegelman BM, Papaioannou V 1992 Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell 71: 577586.
  • 20
    Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, Leonardi A, Tran T, Boyce BF, Siebenlist U 1997 Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 15: 34823496.
  • 21
    Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan H-L, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ 1997 Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89: 309319.
  • 22
    Sly WS, Hewett-Emmett D, Whyte MP, Yu YS, Tashian RE 1983 Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci USA 80: 27522756.
  • 23
    Murphy H 1973 The osteopetrotic syndrome in the microphthalmic mutant mouse. Calcif Tissue Res 13: 1926.
  • 24
    Cleiren E, Benichou O, Van Hul E, Gram J, Bollersley J, Singer FR, Beaverson K, Aledo A, Whyte MP, Yoneyama T, de Vernejoul MC, Van Hul W 2001 Albers-Schonberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet 10: 28612867.
  • 25
    Campos-Xavier AB, Saraiva JM, Ribeiro LM, Munnich A, Cormier-Daire V 2003 Chloride channel 7 (CLCN7) gene mutations mediate autosomal recessive osteopetrosis. Hum Genet 112: 186189.
  • 26
    Kornak U, Kasper D, Bosl MR, Kaiser E, Schweizer M, Schulz A, Friedrich W, Delling G, Jentsch TJ 2001 Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 104: 205215.
  • 27
    Kornak U, Schulz A, Friedrich W, Uhlhaas S, Kremens B, Voit T, Hasan C, Bode U, Jentsch TJ, Kubisch C 2000 Mutations in the A3 subunit of the vacuolar H(+)-ATPase cause infantile malignant osteopetrosis. Hum Mol Genet 9: 20592063.
  • 28
    Frattini A, Orchard PJ, Sobacchi C, Giliani S, Abinun M, Mattsson JP, Keeling DJ, Andersson AK, Wallbrandt P, Zecca L, Notarangelo LD, Vezzoni P, Villa A 2000 Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat Genet 25: 343346.
  • 29
    Chalhoub N, Behachenhou N, Rajapurohitam V, Pata M, Ferron M, Frattini A, Villa A, Vacher J 2003 Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human. Nat Med 9: 399406.
  • 30
    Hughes AE, Ralston SH, Marken J, Bell C, MacPherson H, Wallace R, van Hul W, Whyte MP, Nakatsuka K, Hovy L, Anderson DM 2000 Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet 24: 4548.
  • 31
    Nakatsuka K, Nishizawa Y, Ralston SH 2003 Phenotypic characterization of early onset Paget's disease of bone caused by a 27-bp duplication in the TNFRSF11A gene. J Bone Miner Res 18: 13811385.
  • 32
    Lacey DL, Timms E, Kelley M, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shaloub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165176.
  • 33
    Ikeda T, Utsuyama M, Hirokawa K 2001 Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. J Miner Bone Res 16: 14161425.
  • 34
    Moens CB, Auerbach AB, Conlon RA, Joyner AL, Rossant J 1992 A targeted mutation reveals a role for N-myc in branching morphogenesis in the embryonic mouse lung. Genes Dev 6: 691704.
  • 35
    Smith-Hicks CL, Sizer KC, Powers JF, Tischler AS, Costantini F 2000 C-cell hyperplasia, pheochromocytoma and sympathoadrenal malformation in a mouse model of multiple endocrine neoplasia type 2B. EMBO J 19: 612622.
  • 36
    Eliasson MJ, Blackshaw S, Schell MJ, Snyder SH 1997 Neuronal nitric oxide synthase alternatively spliced forms: Prominent functional localizations in the brain. Proc Natl Acad Sci USA 94: 33963401.
  • 37
    Appleby MW, Gross JA, Cooke MP, Levin SD, Qian X, Perlmutter RM 1992 Defective T cell receptor signalling in mice lacking the thymic isoform of p59fyn. Cell 70: 751763.
  • 38
    Scacheri PC, Crabtree JS, Novotny EA, Garrett-Beal L, Chen A, Edgemon KA, Marx SJ, Spiegel AM, Chandrasekharappa SC, Collins FS 2001 Bidirectional transcriptional activity of PGK-neomycin and unexpected lethality in chimeric knock-out mice. Genesis 30: 259263.
  • 39
    Cundy T, Hegde M, Naot D, Chong B, King A, Wallace R, Mulley J, Love DR, Seidel J, Fawkner M, Banovic T, Callon KE, Grey AB, Reid IR, Middleton-Hardie CA, Cornish J 2002 A mutation in the gene TNFRSF11B encoding osteoprotegerin causes and idiopathic hyperphosphatasia phenotype. Hum Mol Genet 11: 21192127.